title: Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.
abstract: The effect of acute repaglinide administration (2 mg) on postprandial glycaemia and lipaemia has been examined in 20 subjects with type 2 diabetes mellitus. Each subject received in the morning, after a 12 to 14 h fast, a standard mixed meal (total energy 783 kcal), preceded by one tablet of 2 mg repaglinide or placebo. Chylomicrons and chylomicron-deficient plasma were prepared by ultracentrifugation. Triglyceride levels in CM fraction (CM-triglycerides) in total plasma as well as in CM-deficient plasma (non-CM-triglycerides) were determined. A significant reduction in postprandial glycaemia was observed after repaglinide administration compared to placebo ( p < 0.001). Plasma concentrations of total triglycerides, CM-triglycerides, non-CM-triglycerides, free fatty acids and the other plasma lipids measured, were not significantly different between the two phases of the study. It is concluded that, in contrast to sulphonylureas, acute repaglinide administration does not improve postprandial lipaemia in patients with type 2 diabetes.
authors.affiliation: 1st Department of Propaedeutic Medicine, Laiko Hospital, Athens University Medical School, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Tentolouris
authors.forename: M
authors.initials: M
authors.lastname: Kolia
authors.forename: A D
authors.initials: AD
authors.lastname: Tselepis
authors.forename: D
authors.initials: D
authors.lastname: Perea
authors.forename: E
authors.initials: E
authors.lastname: Kitsou
authors.forename: D
authors.initials: D
authors.lastname: Kyriaki
authors.forename: A P
authors.initials: AP
authors.lastname: Tambaki
authors.forename: S P
authors.initials: SP
authors.lastname: Karabina
authors.forename: C
authors.initials: C
authors.lastname: Sala
authors.forename: E
authors.initials: E
authors.lastname: Fragoulopoulos
authors.forename: N
authors.initials: N
authors.lastname: Katsilambros
mesh_terms: D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002219:Carbamates / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007700:Kinetics; D010880:Piperidines / Q000627:therapeutic use*; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D002219:Carbamates; D002784:Cholesterol; D005230:Fatty Acids, Nonesterified; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D014280:Triglycerides; C072379:repaglinide